Atara Biotherapeutics Inc (ATRA) - Financial and Strategic SWOT Analysis Review

Atara Biotherapeutics Inc (ATRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Atara Biotherapeutics Inc (Atara) is a biopharmaceutical company that develops T-cell based immunotherapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. The company is evaluating its lead candidate, tabelecleucel in Phase III clinical trials for the treatment of epstein-barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) following hematopoietic cell transplant and solid organ transplant in patients who refracted rituximab. Its pipeline product candidates that are being developed for multiple indications in various stages of clinical trials include ATA188, ATA2271, ATA3219, ATA3271 and other CAR T programs. Atara is headquartered in San Francisco, California, the US.

Atara Biotherapeutics Inc Key Recent Developments

Dec 07,2020: Atara Biotherapeutics presents first preclinical evaluation of ATA3219, a next-generation allogeneic CD19 CAR T cell therapy, at the 62nd American Society of Hematology (ASH) Annual Meeting
Nov 09,2020: Atara Biotherapeutics announces third quarter 2020 financial results and operational progress
Aug 05,2020: Atara Biotherapeutics announces second quarter 2020 financial results and operational progress
May 14,2020: Atara Biotherapeutics names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development
May 11,2020: Atara Biotherapeutics announces appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to board of directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Section 1 - About the Company
Atara Biotherapeutics Inc - Key Facts
Atara Biotherapeutics Inc - Key Employees
Atara Biotherapeutics Inc - Key Employee Biographies
Atara Biotherapeutics Inc - Major Products and Services
Atara Biotherapeutics Inc - History
Atara Biotherapeutics Inc - Company Statement
Atara Biotherapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Atara Biotherapeutics Inc - Business Description
Atara Biotherapeutics Inc - Corporate Strategy
Atara Biotherapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Atara Biotherapeutics Inc - Strengths
Atara Biotherapeutics Inc - Weaknesses
Atara Biotherapeutics Inc - Opportunities
Atara Biotherapeutics Inc - Threats
Atara Biotherapeutics Inc - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Atara Biotherapeutics Inc, Recent Deals Summary
Section 5 Companys Recent Developments
Dec 07, 2020: Atara Biotherapeutics presents first preclinical evaluation of ATA3219, a next-generation allogeneic CD19 CAR T cell therapy, at the 62nd American Society of Hematology (ASH) Annual Meeting
Nov 09, 2020: Atara Biotherapeutics announces third quarter 2020 financial results and operational progress
Aug 05, 2020: Atara Biotherapeutics announces second quarter 2020 financial results and operational progress
May 14, 2020: Atara Biotherapeutics names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development
May 11, 2020: Atara Biotherapeutics announces appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to board of directors
May 06, 2020: Atara Biotherapeutics announces first quarter 2020 financial results and operational progress
Apr 30, 2020: Atara Biotherapeutics appoints biotech and finance industry veteran Ron Renaud as Non-Executive Chair of the Board of Directors
Apr 02, 2020: Atara Biotherapeutics provides update in context of covid-19 pandemic
Feb 27, 2020: Atara Biotherapeutics announces fourth quarter and full year 2019 financial results and recent clinical, operational and strategic progress
Feb 27, 2020: Atara Biotherapeutics announces fourth quarter and full year 2019 financial results and recent clinical, operational and strategic progress
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables


Atara Biotherapeutics Inc, Key Facts
Atara Biotherapeutics Inc, Key Employees
Atara Biotherapeutics Inc, Key Employee Biographies
Atara Biotherapeutics Inc, Major Products and Services
Atara Biotherapeutics Inc, History
Atara Biotherapeutics Inc, Other Locations
Atara Biotherapeutics Inc, Subsidiaries
Atara Biotherapeutics Inc, Key Competitors
Atara Biotherapeutics Inc, Ratios based on current share price
Atara Biotherapeutics Inc, Annual Ratios
Atara Biotherapeutics Inc, Interim Ratios
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Atara Biotherapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures


Atara Biotherapeutics Inc, Performance Chart (2015 - 2019)
Atara Biotherapeutics Inc, Ratio Charts
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

Atara Biotherapeutics Inc (ATRA) - Financial and Strategic SWOT Analysis Review

Atara Biotherapeutics Inc (ATRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Atara Biotherapeutics Inc (ATRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Atara Biotherapeutics Inc (Atara) is a clinical research company that develops immunotherapies for cancers, autoimmune and severe viral infectious diseases. The company offers clinical stage T-cell product candidates such as

USD 250 View Report

Gene Biotherapeutics Inc (CRXM) - Strategic SWOT Analysis Review

Gene Biotherapeutics Inc (CRXM) - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis,

USD 125 View Report

Gene Biotherapeutics Inc (CRXM) - Financial and Strategic SWOT Analysis Review

Gene Biotherapeutics Inc (CRXM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available